Clinical trials: ES-SCLC
Extensive-stage Small Cell Lung Cancer
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, double-blinded, placebo-controlled phase III, multicenter study is designed to evaluate the safety and efficacy of SHR-1316 in combination with carboplatin plus (+) etoposide compared with treatment with placebo…
- Trial name
- NCT03711305
- Testing
- SHR-1316, Carboplatin, Etoposide
- Where
- 2 sites in China
- Volunteers
- 462 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Extensive Stage Small Cell Lung Cancer
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
- Trial name
- NCT05361395
- Testing
- Tarlatamab, Carboplatin, Etoposide
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 184 people
- Sponsor
- Amgen
Extensive-stage Small-cell Lung Cancer
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive…
- Trial name
- NCT06536868
- Testing
- Tislelizumab, Etoposide, Carboplatin or Cisplatin
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Hospital of Shanxi Medical University
Immunotherapy, Second-line Treatment
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
- Trial name
- NCT05901584
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Extensive Stage Lung Small Cell Carcinoma
Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC
This phase III trial compares the effect of adding radiation therapy to the usual maintenance therapy with adebrelimab versus adebrelimab alone in patients who have already received debrelimab plus chemotherapy for the treatment…
- Trial name
- RALLY (NCT06672133)
- Testing
- Adebrelimab, Radiation Therapy
- Volunteers
- 524 people
- Sponsor
- Jinming Yu
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Cancer Extensive Stage
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
This is a multicenter, open-label, non-randomized, single arm, 2 parts, phase II clinical trial evaluating the efficacy and safety of pembrolizumab and lenvatinib plus standard of care chemotherapy (with carboplatin and etoposide…
- Trial name
- PEERS (NCT05384015)
- Testing
- Lenvatinib, Pembrolizumab, Etoposide
- Where
- 18 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundación GECP
Extensive-stage Small-cell Lung Cancer
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.
- Trial name
- NCT06306560
- Testing
- adebrelimab, famitinib, chemotherapy
- Volunteers
- 40 people
- Sponsor
- Harbin Medical University
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Lung Cancer
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01057342
- Testing
- carboplatin, paclitaxel, vadimezan
- Where
- 12 sites in Switzerland
- Volunteers
- 17 people
- Sponsor
- Swiss Cancer Institute
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions.
- Trial name
- NCT06530797
- Testing
- First-line Adebrelimab regiment for advanced stage ES-SCLC, Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small-cell Lung Cancer
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by…
- Trial name
- NCT05552846
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Extensive-stage Small-cell Lung Cancer
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC).
- Trial name
- MGC018-SCLC (NCT06227546)
- Testing
- MGC018
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Extensive-stage Small Cell Lung Cancer
A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Etoposide-cisplatin/ -carboplatin in combination with PD-L1 inhibitor for 4 cycles followed by maintenance therapy with PD-L1 inhibitor is currently the world-wide first-line treatment for extensive-stage small cell lung cancer.
- Trial name
- NCT04636762
- Testing
- Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
This is a phase 2,open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with small cell lung cancer(SCLC).
- Trial name
- NCT06052423
- Testing
- HS-20093
- Sponsor
- Hansoh BioMedical R&D Company
Extensive-Stage Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus…
- Trial name
- NCT06646276
- Testing
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin
- Where
- 183 sites in United States, Argentina and 24 more
- Volunteers
- 530 people
- Sponsor
- Bristol-Myers Squibb